Poor accrual

Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema

A non-randomized prospective clinical interventional study which includes 45 non previously treated patients with DME. The patients received a single intravitreal injection of 2.5 mg bevacizumab. Follow-up included clinical examination (best corrected visual acuity (BCVA, intraocular pressure (IOP), cataract grading, DME characteristics and systemic check-up) pre-injection, at first visit, at weeks 1 and 2 and months 1 and 3. OCT and fluorescein angiography was evaluated at months 1 and 3.

Inclusion Criteria:

• Type 2 diabetes
• Macular edema involving the center of the macula demonstrated on OCT
• Clear ocular media
• Untreated patients
• Older than 45 years
• BCVA of the fellow eye at least 20/100

Exclusion Criteria:

• Renal diabetic disease, uncontrolled hypertension or stroke history
• Other ocular disease
• Ocular surgery excepting uncomplicated phacoemulsification
• History of photocoagulation (panretinal or focal)
• History of another intravitreal treatment (like triamcinolone)